

Fish oil supplementation modifies the genetic potential for blood lipids

Yitang Sun ¹, Tryggvi McDonald ¹, Abigail Baur ¹, Huifang Xu ¹, Naveen Brahman Bateman ¹,
Ye Shen ², Changwei Li ³, Kaixiong Ye ^{1,4,#}

¹ Department of Genetics, Franklin College of Arts and Sciences, University of Georgia, Athens, GA, USA

² Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens, GA, USA

³ Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA

⁴ Institute of Bioinformatics, University of Georgia, Athens, GA, USA

Corresponding author

Dr. Kaixiong Ye

Department of Genetics

University of Georgia

C220 Davison Life Sciences

120 East Green Street, Athens, GA 30602

Office: 706-542-5898

Fax: 706-542-3910

Email:

Kaixiong.Ye@uga.edu

1 **Abstract**

2

3 **Background**

4 Dyslipidemia is a well-known risk factor for cardiovascular disease, which has been the leading
5 cause of mortality worldwide. Although habitual intake of fish oil has been implicated in
6 offering cardioprotective effects through triglyceride reduction, the interactions of fish oil with
7 the genetic predisposition to dysregulated lipids remain elusive.

8

9 **Objectives**

10 We examined whether fish oil supplementation can modify the genetic potential for the
11 circulating levels of four lipids, including total cholesterol, low-density lipoprotein cholesterol
12 (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides.

13

14 **Methods**

15 A total of 441,985 participants with complete genetic and phenotypic data from the UK Biobank
16 were included in our study. Polygenic scores (PGS) were calculated in participants of diverse
17 ancestries. Multivariable linear regression models were used to assess associations with
18 adjustment for relevant risk factors.

19

20 **Results**

21 Fish oil supplementation mitigated genetic susceptibility to elevated levels of total cholesterol,
22 LDL-C, and triglycerides, while amplifying genetic potential for increased HDL-C among
23 424,090 participants of European ancestry ($P_{\text{interaction}} < 0.05$). Consistent significant findings

24 were obtained using PGS calculated based on multiple genome-wide association studies or
25 alternative PGS methods. We also showed that fish oil significantly attenuated genetic
26 predisposition to high triglycerides in African-ancestry participants.

27

28 **Conclusions**

29 Fish oil supplementation attenuated the genetic susceptibility to elevated blood levels of total
30 cholesterol, LDL-C, and triglycerides, while accentuating genetic potential for higher HDL-C.
31 These results suggest that fish oil may have a beneficial impact on modifying genome-wide
32 genetic effects on elevated lipid levels in the general population.

33 **Introduction**

34

35 Dyslipidemia is well-known to be a major risk factor for cardiovascular disease (CVD), the
36 leading cause of death globally (1). Elevated levels of total cholesterol, low-density lipoprotein
37 cholesterol (LDL-C), and triglyceride serve as major risk factors for increased risks of ischemic
38 events, as shown in epidemiologic and Mendelian randomization studies (2-7). Conversely, a
39 raised level of high-density lipoprotein cholesterol (HDL-C) may have protective roles against
40 CVD, autoimmune disease, and cancers (8, 9). Numerous studies have found that fish oil
41 supplementation, predominantly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA),
42 exerts cardioprotective effects through the reduction of triglyceride level (10-12). However, the
43 roles of fish oil supplementation in modulating genetic susceptibility to elevated lipid levels
44 remains insufficiently investigated.

45

46 In addition to environmental factors, studies have highlighted the essential role of genetic factors
47 in dyslipidemia (13). Genetic effects have been estimated to explain more than 50% of the
48 phenotypic variance in blood lipid levels (14). The differential effect of a genotype in individuals
49 with different environmental exposures, known as gene-environment interaction, also plays a
50 crucial role in determining outcomes (15, 16). A prior genome-wide interaction study identified
51 four novel loci, whose associations with blood lipids were modified by fish oil supplementation
52 (17). Expanding the previous single-variant analysis to a genome-scale, we hypothesized that the
53 genome-wide genetic effects on blood lipid levels, captured by polygenic scores (PGS), could be
54 modified by habitual fish oil supplementation.

55

56 In the current study, we aimed to explore the associations between fish oil supplementation
57 status and genetic predispositions to high levels of total cholesterol, LDL-C, HDL-C, and
58 triglyceride. Large-scale genome-wide association studies (GWAS) have identified numerous
59 single nucleotide polymorphisms (SNPs) significantly associated with elevated lipid levels (18).
60 Leveraging this information and employing novel PGS approaches, we aggregated individual
61 lipid-associated SNPs into genome-scale PGS for estimating the genetic predispositions to high
62 lipids among participants in UK Biobank (UKB). Then, we examined the interaction effects
63 between fish oil supplementation and these PGS on the observed levels of blood lipids. While
64 our primary analysis focused on participants of European (EUR) ancestry, we also investigated
65 the interactions in African (AFR), Central/South Asian (CSA), and East Asian (EAS)
66 populations.

67 **Methods**

68

69 **Study population**

70 This study was conducted using data from UKB (application number 48818), which is a
71 prospective population-based study of over 0.5 million participants aged 37–73 years at
72 recruitment from 2006 to 2010 across the United Kingdom (19). The UKB study received ethical
73 approval from the National Health Service North West Centre for Research Ethics Committee,
74 and all participants provided electronically signed consent before joining the study. Participants
75 provided information on sociodemographic, lifestyle, and medical records via questionnaires at
76 baseline. Blood samples for genotyping and biomarker measurements were also collected at
77 recruitment. Of 502,369 individuals who attended baseline assessment, we excluded 6,705
78 individuals from the analysis due to missing fish oil supplementation data, mismatched
79 information between phenotypic and genetic sex, sex chromosome aneuploidy, outliers for
80 heterogeneity and missing genotype rate, and having a high degree of genetic kinship (ten or
81 more third-degree relatives identified). Our analysis primarily focused on EUR ancestry
82 participants, as they comprised the largest ancestral group in this resource. We also conducted
83 analyses with participants of AFR, CSA, and EAS ancestries. Figure 1 presents a flowchart
84 outlining the inclusion and exclusion of participants throughout our study.

85

86 **Assessment of fish oil supplementation status**

87 The fish oil supplementation status of study participants was determined during their initial
88 assessment center visit using a touchscreen questionnaire. Specifically, participants were asked

89 about their regular consumption of certain supplements, with those reporting fish oil intake
90 (including cod liver oil) classified as supplementing with fish oil.

91

92 **Assessment of blood lipids**

93 Four baseline serum lipid parameters, including total cholesterol, LDL-C, HDL-C, and
94 triglycerides, were ascertained using standard hematological methodologies. These lipids were
95 directly quantified via a robust analytical platform, the Beckman Coulter AU5800 chemistry
96 analyzer, to ensure precision and reproducibility.

97

98 **Polygenic score calculation**

99 We computed PGS for participants of EUR, AFR, CSA, and EAS ancestries in the UKB, which
100 measures the aggregated effects of genetic variants on total cholesterol, LDL-C, HDL-C, and
101 triglycerides. In our primary discovery analysis, we used summary statistics from the largest and
102 most recent GWAS to date, called the Graham SE *et al.* no UKB study, which excluded UKB
103 and included up to 930,672 EUR, 92,555 AFR, and 34,135 CSA ancestry participants (20). In the
104 replication analysis, we employed two additional GWAS summary statistics to calculate PGS.
105 The first is the GWAS meta-analysis using UKB and other cohorts, which was released by
106 Graham SE *et al.*, containing up to 1,320,016 EUR, 99,432 AFR, 40,963 CSA, and 146,492 EAS
107 ancestry participants. The second is a GWAS that included up to 187,365 EUR individuals, as
108 previously reported by Willer CJ *et al.* (21).

109

110 The PGS of UKB participants was calculated with the weighted method: $\text{weighted PGS} = \beta_1 \times$
111 $\text{SNP}_1 + \beta_2 \times \text{SNP}_2 + \dots + \beta_n \times \text{SNP}_n$, where SNP_n is the number of effect alleles of the n^{th} SNP,

112 and the β -coefficient is the effect size of the corresponding allele, which was extracted from
113 GWAS summary statistics. Quality control for genotypic data was based on the following criteria:
114 (1) imputation quality score > 0.3 , (2) minor allele frequency $> 0.1\%$, (3) genotype missingness
115 per individual $< 5\%$, 4) genotype call rate $< 5\%$, and (5) Hardy-Weinberg test P -value $> 1 \times 10^{-8}$.
116 Independent significant SNPs were identified at a GWAS threshold of P -value $< 5 \times 10^{-8}$ with
117 linkage disequilibrium (LD) clumping ($r^2 = 0.1$, 250 kb). We also utilized the PGS β -coefficient
118 previously generated by Weissbrod O *et al.* employing the methods of PolyPred, PolyPred+, and
119 LD-pruning + P -value thresholding (P+T) (clump $r^2 = 0.5$, 250 kb) (22). To facilitate the
120 comparison of effects across four blood lipids, PGS was standardized to a mean of 0 and a
121 standard deviation (SD) of 1, enabling interpretation per one SD change.

122

123 **Covariates**

124 A series of sociodemographic, behavioral, and genetic covariates were included in our study.
125 Age, sex, and body mass index (BMI) were obtained from baseline assessments at recruitment.
126 The 22 baseline assessment center locations were situated throughout England, Scotland, and
127 Wales. Socioeconomic status, as calculated by the Townsend deprivation index, was assigned to
128 each participant corresponding to their home postcode at recruitment. Smoking and alcohol
129 drinking status were defined as never, former, and current. Physical activity levels were
130 categorized as low, moderate, and high following the International Physical Activity
131 Questionnaire protocol. Statin use was ascertained through self-report during verbal interviews.
132 Genetic data were generated through genotyping by either the UK Biobank Axiom Array or the
133 UK BiLEVE Array. Participants were divided into ancestry groups based on the multi-ancestry

134 analysis from the Pan-ancestry genetic analysis of the UK Biobank (Pan-UKBB). The top 20
135 ancestry principal components derived from the Pan-UKBB were employed as covariates.

136

137 **Statistical analysis**

138 Multivariable linear regression models were conducted to assess the modifying impacts of fish
139 oil supplementation on the genetic potential for blood lipids. Two groups of covariates were used
140 to apply these models. In the first model, we adjusted for sex, age, age², assessment centers,
141 genotyping array, and the top 20 genetic principal components. The second model added
142 additional covariates, including BMI, Townsend deprivation index, smoking status, alcohol
143 status, physical activity, and statin use. We investigated the association between lipid PGS and
144 lipid levels, stratifying by fish oil intake status among 424,090 participants of EUR ancestry to
145 scrutinize the influence of fish oil supplementation on genetic predisposition for lipid levels. We
146 further examined interactions between fish oil supplementation and PGS for four lipids on lipid
147 levels by adding an interaction term between fish oil intake and lipid PGS and by incorporating
148 both fish oil supplementation status and PGS as covariates in both models. Moreover, we
149 conducted these interaction analyses using 6,577 AFR, 8,648 CSA, and 2,670 EAS ancestry
150 participants. Serum levels of total cholesterol, LDL-C, HDL-C, and triglycerides were
151 standardized, and their comparable effect sizes were expressed per one SD increase in the
152 corresponding blood lipid. All analyses were conducted using R (version 4.2.1).

153 **Results**

154

155 **Study cohorts**

156 A total of 441,985 participants from the UKB with complete genetic and phenotypic data were
157 included in this study, consisting mostly of individuals of EUR ancestry and a small proportion
158 of other ancestries. We present the baseline characteristics of participants of EUR ancestry
159 according to their fish oil intake status at baseline in Table 1. After quality control, 134,720
160 (31.8%) of study participants reported habitual use of fish oil supplements, while the remaining
161 289,370 participants were grouped as non-consumers of fish oil. The majority of fish oil users
162 were women (56%), with a mean age of 59 years. Those in the fish oil intake group were more
163 likely to be older, female, current alcohol drinkers, statin users, engaging in high physical
164 activity, and having higher levels of total cholesterol, LDL-C, and HDL-C, but less likely to be
165 current smokers or have an elevated BMI or triglyceride level. Among other ancestry groups,
166 2,289 (34.8%) AFR, 1,942 (22.5%) CSA, and 845 (31.6%) EAS participants took fish oil
167 supplementation and displayed similar characteristics to the EUR participants (Supplementary
168 Table 1).

169

170 **Effect modification by fish oil supplementation on genetic predisposition to elevated lipids**

171 In general, fish oil supplementation provided protection against genetic susceptibility to elevated
172 levels of total cholesterol, LDL-C, and triglycerides, while it amplified genetic potential for
173 higher HDL-C level. For the primary analysis using PGS (excluded UKB, Graham SE *et al.*),
174 there was strong evidence that fish oil supplementation modified the effect of the genetic
175 potential for four lipids in either the partially or fully adjusted model ($P_{\text{interaction}} < 0.05$) (Figure 2

176 and Table 2). When we generated PGS using two other GWAS summary statistics of Graham SE
177 *et al.* (included UKB) and Willer CJ *et al.*, consistently significant results were observed for the
178 four lipids (Supplementary Figure 1 and Supplementary Table 2). We also calculated PGS based
179 on the β -coefficient previously generated by Weissbrod O *et al.* employing PolyPred, which is
180 another PGS method employing functionally informed fine-mapping methods to obtain the
181 posterior association coefficients. Utilizing PGS calculated via the PolyPred and P+T methods,
182 we also discovered that fish oil supplementation significantly modified the genetic potential for
183 elevated blood lipids (Supplementary Figure 2 and Supplementary Table 2).

184

185 In the stratified analysis, fish oil supplementation significantly attenuated the genetic association
186 with total cholesterol: each 1 SD increase in PGS was associated with a 0.304 SD increase (95%
187 CI = 0.299 – 0.309) in total cholesterol among fish oil supplement users, compared to a 0.313 SD
188 increase (95% CI = 0.310 – 0.317) among non-users (Figure 2 and Table 2). Similarly, for LDL-
189 C, a 1 SD increment in PGS resulted in an increase of 0.323 SD (95% CI = 0.318 – 0.328) in
190 LDL-C level among fish oil users, in comparison to 0.332 SD increase (95% CI = 0.328 – 0.335)
191 for people without fish oil intake. Genetic susceptibility to high triglycerides was 0.254 (95% CI
192 = 0.248 – 0.259) in the fish oil group and 0.267 (95% CI = 0.263 – 0.270) in the group not taking
193 fish oil. Lastly, the impact of PGS was more pronounced in the fish oil group (0.234, 95% CI =
194 0.229 – 0.240) for HDL-C compared to participants without fish oil intake (0.227, 95% CI =
195 0.224 – 0.231). In summary, fish oil supplementation attenuates the genetic potential for elevated
196 levels of total cholesterol, LDL-C, and triglycerides, while amplifying the genetic predisposition
197 to a high level of HDL-C.

198

199 **Interaction effects in other ancestry groups**

200 In participants of AFR ancestry from UKB, we found that fish oil supplementation was
201 consistently associated with a diminished risk of genetic susceptibility to high triglycerides
202 (Supplementary Table 3). When stratified by fish oil supplementation status, each SD increase in
203 PGS correlated to a 0.099 SD (95% CI = 0.070 – 0.128) rise in triglyceride level among fish oil
204 users, compared to a 0.150 SD (95% CI = 0.125 – 0.174) increase among those not taking fish
205 oil. However, this modification effect of fish oil supplementation was not observed in
206 participants of CSA and EAS ancestries (Supplementary Tables 4 and 5). Moreover, analyses
207 involving participants from other ancestry groups did not indicate significant interaction effects
208 on total cholesterol, LDL-C, and HDL-C. In these diverse populations, the influence of PGS on
209 lipid levels remained statistically significant even after adjusting for fish oil supplementation and
210 multiple covariates (Supplementary Table 6).

211 **Discussion**

212

213 In this extensive prospective study involving 424,090 participants of EUR ancestry, our results
214 indicated that fish oil supplementation could modify the genetic susceptibility to elevated levels
215 of four lipids. Our findings suggested that fish oil supplementation attenuated genetic
216 predispositions to high levels of total cholesterol, LDL-C, and triglycerides, while accentuating
217 the genetic potential for increased HDL-C level. Analyzing 6,577 AFR, 8,648 CSA, and 2,670
218 EAS ancestry participants, no consistent significant interactions were found. However, for
219 participants of AFR ancestry, our results indicated that fish oil supplementation mitigates the
220 genetic risk on increased triglycerides. Collectively, our findings supported the hypothesis that
221 genome-wide genetic effects on blood lipid levels, captured by PGS, could be modified by
222 habitual fish oil supplementation.

223

224 Although substantial studies have highlighted the effects of fish oil supplements in improving the
225 lipid profile in hyperlipidemic patients, their influence on genetic susceptibility to dyslipidemia
226 remains unclear (2, 11, 23-26). A recent dose-response meta-analysis of 90 randomized
227 controlled trials with 72,598 participants demonstrated that DHA+ ω -3 EPA supplementation (>2
228 g/d) reduced triglyceride level (27). Skulas-Ray AC *et al.* concluded that pharmacological doses
229 of omega-3 fatty acids (>3 g/d total EPA+DHA) effectively decrease triglycerides and can be
230 safely combined with other lipid-lowering agents, particularly statins (28). The Japan EPA Lipid
231 Intervention Study, involving 14,981 hypercholesterolemia Japanese patients, found that 1.8 g/d
232 EPA in combination with a statin led to lower triglycerides compared with statin therapy alone
233 (29). In the current study of non-EUR ancestry groups, we also observed fish oil attenuates

234 genetic susceptibility to elevated triglycerides among participants of AFR ancestry, but no
235 significant interaction was detected among participants of CSA and EAS ancestries, which may
236 be due to insufficient sample sizes. Large-scale studies covering more representative samples
237 from diverse ancestries are needed to further validate our findings. Regarding genetic factors,
238 some studies have investigated the interactions between fish oil and lipid-related genetic variants
239 (17, 30-33). Our findings, leveraging cumulative effects of many genetic variants across the
240 genome to assess individual genetic predisposition to dyslipidemia, affirmed the protective role
241 of fish oil against genetic susceptibility to dyslipidemia.

242

243 The precise mechanisms underlying the observed interactions between fish oil supplementation
244 and genetic predisposition to elevated lipid levels are not yet fully elucidated. These modifying
245 effects could potentially be attributed to the multifaceted benefits derived from fish oil
246 supplements. The putative mechanisms through which fish oil supplementation influences
247 human lipoprotein metabolism include inhibition of very low-density lipoprotein (VLDL)
248 triglyceride synthesis, decreased apoprotein B synthesis, enhancement of VLDL turnover via an
249 increased fractional catabolic rate of VLDL, depression of LDL synthesis, and reduction of
250 postprandial lipemia (34). Additionally, fish oil intake has been found to exert beneficial effects
251 on several factors implicated in cardiovascular health, including inflammatory, oxidative,
252 thrombotic, vascular, and arrhythmogenic parameters (11, 35-40). However, it is plausible that
253 other mechanisms may also be involved in this modifying effect. Future functional studies are
254 warranted to discern the underlying biological mechanisms.

255

256 To the best of our knowledge, this is the first study to evaluate the modifying effects of fish oil
257 supplementation on genetic susceptibility to elevated lipid levels. The major strength of our
258 study lies in the large number of participants of EUR ancestry, providing sufficient statistical
259 power to detect significant interactions. Another strength of our study is the inclusion of other
260 ancestry groups, where we confirmed that fish oil attenuated genetic susceptibility to high
261 triglycerides in the AFR population. We used various GWAS summary statistics and PGS
262 methodologies to calculate PGS and applied a fully adjusted model with a wealth of data on
263 covariates, including socioeconomic characteristics, lifestyle factors, and statin use. Notably, the
264 PGS for the primary analysis incorporated multiple SNPs from the largest and most recent
265 GWAS across different cohorts, excluding any sample overlap with the UKB, thereby
266 circumventing the potential issue of spurious candidate gene interactions (41). Population
267 structure can lead to inflated estimates of PGS prediction (41). To address this, we adjusted all
268 models for the top 20 genetic principal components to minimize potential bias. This
269 comprehensive study design ensured the robustness and consistency of our findings.

270

271 Several potential limitations should also be considered. First, the self-reported fish oil intake is
272 vulnerable to both measurement error and recall bias. Second, since fish oil supplementation
273 status was assessed only at baseline, we were unable to evaluate the effects of longitudinal
274 changes or extended duration of use. Third, our data lacked details on specific doses of fish oil
275 supplementation, and future research is needed to discern the independent roles of DHA and
276 EPA at specific doses. Fourth, UKB recruited people aged between 37 and 73 years at baseline,
277 and our findings may not be generalizable to other age groups, such as children and adolescents
278 (42). Fifth, though our study included multiple ancestries, caution is advised when extrapolating

279 our findings to non-EUR populations, and future investigations with larger sample sizes are
280 necessary. Lastly, given the observational design of our study, we cannot completely rule out
281 reverse causation or residual confounding.

282

283 In conclusion, our findings reveal that fish oil supplementation attenuates genetic susceptibility
284 to elevated blood levels of total cholesterol, LDL-C, and triglycerides, while accentuating
285 genetic potential for higher HDL-C. Moreover, we detected fish oil modulates genetic
286 predisposition to high triglycerides among participants of AFR ancestry. These findings suggest
287 that fish oil could serve a beneficial role in modulating genetic susceptibility to elevated lipid
288 levels in the general population. Further studies with larger sample sizes from diverse ancestry
289 and accurate dose information of fish oil supplements are warranted to corroborate and expand
290 our findings.

291 **Acknowledgments**

292 The authors' responsibilities were as follows—YS and KY: designed the study; YS: performed
293 data analysis, prepared visualizations, and wrote the original draft of the manuscript; TM, AB,
294 HX, and NBB: contributed to the data analysis; YS, YS (yeshen@uga.edu), CL, and KY:
295 provided statistical advice; YS and KY: interpreted the results; KY: critically revised the paper;
296 all authors: read and approved the final manuscript and took responsibility for the integrity of the
297 work as a whole.

298

299 **Disclosure**

300 The authors declare that there is no conflict of interest.

301

302 **Funding**

303 This work was funded by the University of Georgia Research Foundation and by the National
304 Institute of General Medical Sciences of the National Institutes of Health under Award Number
305 R35GM143060. The content is solely the responsibility of the authors and does not necessarily
306 represent the official views of the National Institutes of Health.

307

308

309 **Data availability**

310 Access to the UK Biobank resource is available via the application
311 (<http://www.ukbiobank.ac.uk>). PGS coefficients generated by Graham SE *et al.* are available for
312 public download at <http://csg.sph.umich.edu/willer/public/glgc->

313 [lipids2021/results/ancestry_specific/](#). PGS coefficients generated by Willer CJ *et al.* are available
314 for public download at
315 [http://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST002001-
GCST003000/GCST002221/harmonised/](http://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST002001-
GCST003000/GCST002221/harmonised/). PGS coefficients generated by Weissbrod O *et al.* are
317 available for public download at https://alkesgroup.broadinstitute.org/polypred_results.
318

References

1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. *J Am Coll Cardiol* 2020;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010.
2. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Jr., Juliano RA, Jiao L, Granowitz C, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. *N Engl J Med* 2019;380(1):11-22. doi: 10.1056/NEJMoa1812792.
3. Libby P. Triglycerides on the rise: should we swap seats on the seesaw? *Eur Heart J* 2015;36(13):774-6. doi: 10.1093/eurheartj/ehu500.
4. Klempfner R, Erez A, Sagit BZ, Goldenberg I, Fisman E, Kopel E, Shlomo N, Israel A, Tenenbaum A. Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry. *Circ Cardiovasc Qual Outcomes* 2016;9(2):100-8. doi: 10.1161/CIRCOUTCOMES.115.002104.
5. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J* 2017;38(32):2459-72. doi: 10.1093/eurheartj/ehx144.

6. Toth PP, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real-World Administrative Claims Analysis of Statin-Treated Patients With High Residual Cardiovascular Risk. *J Am Heart Assoc* 2018;7(15):e008740. doi: 10.1161/JAHA.118.008740.
7. Harris WS, Ginsberg HN, Arunakul N, Shachter NS, Windsor SL, Adams M, Berglund L, Osmundsen K. Safety and efficacy of Omacor in severe hypertriglyceridemia. *J Cardiovasc Risk* 1997;4(5-6):385-91.
8. von Eckardstein A, Nordestgaard BG, Remaley AT, Catapano AL. High-density lipoprotein revisited: biological functions and clinical relevance. *Eur Heart J* 2023;44(16):1394-407. doi: 10.1093/eurheartj/ehac605.
9. Manson JE, Bassuk SS, Cook NR, Lee IM, Mora S, Albert CM, Buring JE, Group VR. Vitamin D, Marine n-3 Fatty Acids, and Primary Prevention of Cardiovascular Disease Current Evidence. *Circ Res* 2020;126(1):112-28. doi: 10.1161/CIRCRESAHA.119.314541.
10. Zhang Y, Sun Y, Yu Q, Song S, Brenna JT, Shen Y, Ye K. Higher ratio of plasma omega-6/omega-3 fatty acids is associated with greater risk of all-cause, cancer, and cardiovascular mortality: a population-based cohort study in UK Biobank. *medRxiv* 2023:2023.01.16.23284631. doi: 10.1101/2023.01.16.23284631.
11. Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk:

- The STRENGTH Randomized Clinical Trial. *JAMA* 2020;324(22):2268-80. doi: 10.1001/jama.2020.22258.
12. Grevengoed TJ, Trammell SA, Svenningsen JS, Makarov MV, Nielsen TS, Jacobsen JCB, Treebak JT, Calder PC, Migaud ME, Cravatt BF, et al. An abundant biliary metabolite derived from dietary omega-3 polyunsaturated fatty acids regulates triglycerides. *J Clin Invest* 2021;131(6). doi: 10.1172/JCI143861.
 13. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, et al. Biological, clinical and population relevance of 95 loci for blood lipids. *Nature* 2010;466(7307):707-13. doi: 10.1038/nature09270.
 14. Liu H, Wang W, Zhang C, Xu C, Duan H, Tian X, Zhang D. Heritability and Genome-Wide Association Study of Plasma Cholesterol in Chinese Adult Twins. *Front Endocrinol (Lausanne)* 2018;9:677. doi: 10.3389/fendo.2018.00677.
 15. Corraini P, Olsen M, Pedersen L, Dekkers OM, Vandenbroucke JP. Effect modification, interaction and mediation: an overview of theoretical insights for clinical investigators. *Clin Epidemiol* 2017;9:331-8. doi: 10.2147/CLEP.S129728.
 16. Ottman R. Gene-environment interaction: definitions and study designs. *Prev Med* 1996;25(6):764-70. doi: 10.1006/pmed.1996.0117.
 17. Francis M, Li C, Sun Y, Zhou J, Li X, Brenna JT, Ye K. Genome-wide association study of fish oil supplementation on lipid traits in 81,246 individuals reveals new gene-diet interaction loci. *PLoS Genet* 2021;17(3):e1009431. doi: 10.1371/journal.pgen.1009431.
 18. !!! INVALID CITATION !!! (18, 19).

19. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med* 2015;12(3):e1001779. doi: 10.1371/journal.pmed.1001779.
20. Graham SE, Clarke SL, Wu KH, Kanoni S, Zajac GJM, Ramdas S, Surakka I, Ntalla I, Vedantam S, Winkler TW, et al. The power of genetic diversity in genome-wide association studies of lipids. *Nature* 2021;600(7890):675-9. doi: 10.1038/s41586-021-04064-3.
21. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, Ganna A, Chen J, Buchkovich ML, Mora S, et al. Discovery and refinement of loci associated with lipid levels. *Nat Genet* 2013;45(11):1274-83. doi: 10.1038/ng.2797.
22. Weissbrod O, Kanai M, Shi H, Gazal S, Peyrot WJ, Khera AV, Okada Y, Biobank Japan P, Martin AR, Finucane HK, et al. Leveraging fine-mapping and multipopulation training data to improve cross-population polygenic risk scores. *Nat Genet* 2022;54(4):450-8. doi: 10.1038/s41588-022-01036-9.
23. Investigators OT, Bosch J, Gerstein HC, Dagenais GR, Diaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. *N Engl J Med* 2012;367(4):309-18. doi: 10.1056/NEJMoa1203859.
24. Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management. *J Am Coll Cardiol* 2018;72(3):330-43. doi: 10.1016/j.jacc.2018.04.061.

25. Abdelhamid AS, Martin N, Bridges C, Brainard JS, Wang X, Brown TJ, Hanson S, Jimoh OF, Ajabnoor SM, Deane KH, et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2018;7(7):CD012345. doi: 10.1002/14651858.CD012345.pub2.
26. Marston NA, Giugliano RP, Im K, Silverman MG, O'Donoghue ML, Wiviott SD, Ference BA, Sabatine MS. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. *Circulation* 2019;140(16):1308-17. doi: 10.1161/CIRCULATIONAHA.119.041998.
27. Wang T, Zhang X, Zhou N, Shen Y, Li B, Chen BE, Li X. Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials. *J Am Heart Assoc* 2023;12(11):e029512. doi: 10.1161/JAHA.123.029512.
28. Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, Jacobson TA, Engler MB, Miller M, Robinson JG, et al. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. *Circulation* 2019;140(12):e673-e91. doi: 10.1161/CIR.0000000000000709.
29. Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). *Atherosclerosis* 2008;200(1):135-40. doi: 10.1016/j.atherosclerosis.2008.06.003.

30. Madden J, Williams CM, Calder PC, Lietz G, Miles EA, Cordell H, Mathers JC, Minihane AM. The impact of common gene variants on the response of biomarkers of cardiovascular disease (CVD) risk to increased fish oil fatty acids intakes. *Annu Rev Nutr* 2011;31:203-34. doi: 10.1146/annurev-nutr-010411-095239.
31. Ferguson JF, Phillips CM, McMonagle J, Perez-Martinez P, Shaw DI, Lovegrove JA, Helal O, Defoort C, Gjelstad IM, Drevon CA, et al. NOS3 gene polymorphisms are associated with risk markers of cardiovascular disease, and interact with omega-3 polyunsaturated fatty acids. *Atherosclerosis* 2010;211(2):539-44. doi: 10.1016/j.atherosclerosis.2010.03.027.
32. Lindi V, Schwab U, Louheranta A, Laakso M, Vessby B, Hermansen K, Storlien L, Riccardi G, A AR, Group KS. Impact of the Pro12Ala polymorphism of the PPAR-gamma2 gene on serum triacylglycerol response to n-3 fatty acid supplementation. *Mol Genet Metab* 2003;79(1):52-60. doi: 10.1016/s1096-7192(03)00065-9.
33. Madden J, Carrero JJ, Brunner A, Dastur N, Shearman CP, Calder PC, Grimble RF. Polymorphisms in the CD36 gene modulate the ability of fish oil supplements to lower fasting plasma triacyl glycerol and raise HDL cholesterol concentrations in healthy middle-aged men. *Prostaglandins Leukot Essent Fatty Acids* 2008;78(6):327-35. doi: 10.1016/j.plefa.2008.04.003.
34. Stone NJ. Fish consumption, fish oil, lipids, and coronary heart disease. *Circulation* 1996;94(9):2337-40. doi: 10.1161/01.cir.94.9.2337.
35. Duda MK, O'Shea KM, Lei B, Barrows BR, Azimzadeh AM, McElfresh TE, Hoit BD, Kop WJ, Stanley WC. Dietary supplementation with omega-3 PUFA increases adiponectin and

- attenuates ventricular remodeling and dysfunction with pressure overload. *Cardiovasc Res* 2007;76(2):303-10. doi: 10.1016/j.cardiores.2007.07.002.
36. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. *J Am Coll Cardiol* 2009;54(7):585-94. doi: 10.1016/j.jacc.2009.02.084.
37. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. *J Am Coll Cardiol* 2011;58(20):2047-67. doi: 10.1016/j.jacc.2011.06.063.
38. Tribulova N, Szeiffova Bacova B, Egan Benova T, Knezl V, Barancik M, Slezak J. Omega-3 Index and Anti-Arrhythmic Potential of Omega-3 PUFAs. *Nutrients* 2017;9(11). doi: 10.3390/nu9111191.
39. Stirban A, Nandreaan S, Gotting C, Tamler R, Pop A, Negrean M, Gawlowski T, Stratmann B, Tschoepe D. Effects of n-3 fatty acids on macro- and microvascular function in subjects with type 2 diabetes mellitus. *Am J Clin Nutr* 2010;91(3):808-13. doi: 10.3945/ajcn.2009.28374.
40. Lee JH, O'Keefe JH, Lavie CJ, Harris WS. Omega-3 fatty acids: cardiovascular benefits, sources and sustainability. *Nat Rev Cardiol* 2009;6(12):753-8. doi: 10.1038/nrcardio.2009.188.
41. Choi SW, Mak TS, O'Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. *Nat Protoc* 2020;15(9):2759-72. doi: 10.1038/s41596-020-0353-1.
42. Frensham LJ, Bryan J, Parletta N. Influences of micronutrient and omega-3 fatty acid supplementation on cognition, learning, and behavior: methodological considerations

and implications for children and adolescents in developed societies. *Nutr Rev*

2012;70(10):594-610. doi: 10.1111/j.1753-4887.2012.00516.x.

Figure and Table captions

Main Tables

Table 1. Baseline characteristics of participants of European ancestry in the UK Biobank^a

	Fish oil intake (n=134720)	No fish oil intake (n=289370)	P-value
Age, years (SD)	59 (7.3)	56 (8.1)	<0.001
Sex, female (%)	75726 (56)	153758 (53)	<0.001
Body mass index, kg/m² (SD)	27 (4.5)	28 (4.9)	<0.001
Total cholesterol, mmol/L (SD)	5.78 (1.16)	5.68 (1.14)	<0.001
LDL cholesterol, mmol/L (SD)	3.61 (0.88)	3.55 (0.87)	<0.001
HDL cholesterol, mmol/L (SD)	1.48 (0.39)	1.44 (0.38)	<0.001
Triglycerides, mmol/L (SD)	1.75 (1.00)	1.76 (1.04)	0.036

	Fish oil intake (n=134720)	No fish oil intake (n=289370)	P-value
Smoking status (%)			<0.001
Never	71756 (53)	157498 (54)	
Previous	51940 (39)	97930 (34)	
Current	10527 (8)	32968 (11)	
Alcohol status (%)			<0.001
Never	4075 (3)	9220 (3)	
Previous	4302 (3)	10411 (4)	
Current	126232 (94)	269500 (93)	
Physical activity (%)			<0.001
Low	16930 (13)	47061 (16)	
Moderate	43674 (32)	96758 (33)	
High	48761 (36)	90921 (31)	
Statin use, yes (%)	24121 (18)	45463 (16)	<0.001

^a Values are numbers (%) for categorical variables, and mean (SD) for continuous variables. P-values were obtained from the Chi-squared test (categorical variables) or the 2-sample t-test (continuous variables). LDL, low-density lipoprotein; HDL, high-density lipoprotein.

Table 2. Association of lipid polygenic scores with observed lipid levels stratified by the fish oil intake status in UKB participants of European ancestry using GWAS summary statistics from Graham SE *et al.* (excluded UKB)^a

Lipids	Fish oil intake			No fish oil intake			$P_{\text{interaction}}^b$
	n	β (95% CI)	P -value	n	β (95% CI)	P -value	
Total cholesterol, SD							
Partially adjusted association ^c	128634	0.244 (0.239, 0.249)	$<2.0 \times 10^{-16}$	276134	0.265 (0.261, 0.268)	$<2.0 \times 10^{-16}$	9.98×10^{-12}
Fully adjusted association ^d	103738	0.304 (0.299, 0.309)	$<2.0 \times 10^{-16}$	222391	0.313 (0.310, 0.317)	$<2.0 \times 10^{-16}$	3.53×10^{-4}
LDL cholesterol, SD							
Partially adjusted association ^c	128393	0.262 (0.257, 0.267)	$<2.0 \times 10^{-16}$	275625	0.280 (0.277, 0.284)	$<2.0 \times 10^{-16}$	6.27×10^{-9}
Fully adjusted association ^d	103538	0.323 (0.318, 0.328)	$<2.0 \times 10^{-16}$	221994	0.332 (0.328, 0.335)	$<2.0 \times 10^{-16}$	0.001
HDL cholesterol, SD							
Partially adjusted association ^c	117709	0.235 (0.230, 0.240)	$<2.0 \times 10^{-16}$	252786	0.230 (0.227, 0.234)	$<2.0 \times 10^{-16}$	0.139
Fully adjusted association ^d	94880	0.234 (0.229, 0.240)	$<2.0 \times 10^{-16}$	203514	0.227 (0.224, 0.231)	$<2.0 \times 10^{-16}$	0.025
Triglycerides, SD							
Partially adjusted association ^c	128544	0.252 (0.247, 0.257)	$<2.0 \times 10^{-16}$	275897	0.265 (0.262, 0.269)	$<2.0 \times 10^{-16}$	2.45×10^{-5}
Fully adjusted association ^d	103674	0.254 (0.248, 0.259)	$<2.0 \times 10^{-16}$	222215	0.267 (0.263, 0.270)	$<2.0 \times 10^{-16}$	5.42×10^{-5}

^a UKB, UK Biobank; SD, standard deviation; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

^b *P*-value was obtained from the interaction term between lipid PGS and fish oil supplementation. Models were adjusted for lipids PGS, fish oil supplementation, sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.

^c Models were adjusted for sex, age, age², assessment centers, genotyping array, and the top 20 genetic principal components.

^d Models were adjusted for sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.

Figure and Table captions

Main Figures

Figure 1. Flowchart of the study population selection.

UKB, UK Biobank; Pan-UKBB, Pan-ancestry genetic analysis of the UK Biobank; EUR, European; AFR, African; CSA, Central/South Asian; EAS, East Asian; GWAS, genome-wide association study; PGS, polygenic scores.

Figure 2. Interaction between fish oil and genetic predisposition to elevated blood lipids using GWAS summary statistics from Graham SE *et al.* (excluded UKB).

Effect estimates and 95% confidence intervals are scaled to per 1 SD increase in PGS measured in SD units. UKB, UK Biobank; GWAS, genome-wide association study; PGS, polygenic scores; Pint, *P*-value for interaction.

Supplementary Figures

Supplementary Figure 1. Interaction between fish oil and genetic predisposition to elevated blood lipids using GWAS summary statistics from Graham SE *et al.* (included UKB) and Willer CJ *et al.*

Effect estimates and 95% confidence intervals are scaled to per 1 SD increase in PGS measured in SD units. UKB, UK Biobank; GWAS, genome-wide association study; PGS, polygenic scores; Pint, *P*-value for interaction.

Supplementary Figure 2. Interaction between fish oil and genetic predisposition to elevated blood lipids using the PGS β -coefficient generated by Weissbrod O *et al.*, including PolyPred and P+T.

Effect estimates and 95% confidence intervals are scaled to per 1 SD increase in PGS measured in SD units. PGS, polygenic scores; Pint, *P*-value for interaction.

Supplementary Tables

Supplementary Table 1. Baseline characteristics of participants of African, Central/South Asian, and East Asian ancestries in the UK Biobank ^a

^a Values are numbers (%) for categorical variables, and mean (SD) for continuous variables. LDL, low-density lipoprotein; HDL, high-density lipoprotein.

Supplementary Table 2. Association of lipid polygenic scores with observed lipid levels stratified by the fish oil intake status in participants of European ancestry^a

^a UKB, UK Biobank; SD, standard deviation; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

^b *P*-value was obtained from the interaction term between lipid PGS and fish oil supplementation. Models were adjusted for lipids PGS, fish oil supplementation, sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.

^c Models were adjusted for sex, age, age², assessment centers, genotyping array, and the top 20 genetic principal components.

^d Models were adjusted for sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.

Supplementary Table 3. Association of lipid polygenic scores with observed lipid levels stratified by the fish oil intake status in participants of African ancestry^a

^a UKB, UK Biobank; SD, standard deviation; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

^b *P*-value was obtained from the interaction term between lipid PGS and fish oil supplementation. Models were adjusted for lipids PGS, fish oil supplementation, sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.

^c Models were adjusted for sex, age, age², assessment centers, genotyping array, and the top 20 genetic principal components.

^d Models were adjusted for sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.

Supplementary Table 4. Association of lipid polygenic scores with observed lipid levels stratified by the fish oil intake status in participants of Central/South Asian ancestry^a

^a UKB, UK Biobank; SD, standard deviation; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

^b *P*-value was obtained from the interaction term between lipid PGS and fish oil supplementation. Models were adjusted for lipids PGS, fish oil supplementation, sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.

^c Models were adjusted for sex, age, age², assessment centers, genotyping array, and the top 20 genetic principal components.

^d Models were adjusted for sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.

Supplementary Table 5. Association of lipid polygenic scores with observed lipid levels stratified by the fish oil intake status in participants of East Asian ancestry^a

^a UKB, UK Biobank; SD, standard deviation; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

^b *P*-value was obtained from the interaction term between lipid PGS and fish oil supplementation. Models were adjusted for lipids PGS, fish oil supplementation, sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.

^c Models were adjusted for sex, age, age², assessment centers, genotyping array, and the top 20 genetic principal components.

^d Models were adjusted for sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.


Supplementary Table 6. Effects of fish oil supplementation and PGS on observed lipid levels in UKB participants of diverse ancestries^a

^a UKB, UK Biobank; SD, standard deviation; LDL, low-density lipoprotein; HDL, high-density lipoprotein; EUR, European; AFR, African; CSA, Central/South Asian; EAS, East Asian.

^b Models were adjusted for sex, age, age², assessment centers, genotyping array, and the top 20 genetic principal components.

^c Models were adjusted for sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.

Figure 1



It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

Figure 2

